Background: A qPCR assay with single copy sensitivity targeting HIV-1 gag (gSCA) has been widely used to quantify plasma HIV-1 RNA below the limit of clinical assays. However, with current extraction methods, gSCA incompletely recovers a spiked internal standard (avian sarcoma virus, RCAS), and fails to efficiently amplify 15-30% of HIV-1 subtype B sequences due to mismatches in the gag primer/probe binding sites. To address these limitations, we developed a next generation SCA with improved extraction efficiency and primers/probes targeting highly conserved sequences in integrase (iSCA). We also explored assaying larger plasma volumes to increase iSCA sensitivity (Mega-iSCA). Methodology: Primers/probe for qPCR were designed to target a highly conserved 3’ region of HIV-1 integrase away from drug-resistance sites. Recovery of the spiked internal standard RCAS was used to optimize the extraction method. Paired plasma samples from 30 consecutive donors (25 with suppressed viremia for >2 years; 5 with viremia >50 copies/mL) were obtained to compare iSCA versus gSCA. For viremic patients, HIV-1 RNA recovery <10% of Roche TaqMan v2.0 was scored as inefficient amplification. Between iSCA and gSCA, >3-fold differences in HIV-1 RNA were considered significant. Large plasma volumes (up to 34 ml) were assayed by Mega-iSCA to achieve a theoretical limit of detection (LOD) of 0.05 copies/mL. Results: Testing of the plasma panel from 30 donors revealed that the median recovery of the internal standard was 1.5 times higher with iSCA compared to gSCA (p<0.001, signed rank test). In samples from the 5 patients with viremia >50 copies/mL, gSCA efficiently amplified 2 of 5 whereas iSCA efficiently amplified all 5 compared with TaqMan (p=0.01, exact binomial test). In samples from all 30 patients, 12 of 30 had >3-fold recovery of HIV-1 RNA with iSCA versus gSCA, while 3 of 30 had >3-fold recovery with gSCA (p<0.001, exact binomial test). Using gSCA, 11 of 30 samples were undetectable compared with 7 of 30 samples using iSCA (p=0.088, exact binomial test). Large volume plasma samples from 7 patients with HIV-1 RNA <50 copies/mL were assayed by Mega-iSCA (4 of 7 were negative by standard iSCA). Mega-iSCA detected HIV-1 RNA in 6 of 7 samples including 3 of 4 negative by standard iSCA. Conclusions: An optimized extraction method and primers/probe targeting highly conserved sequences in the 3’ region of pol improved viral RNA recovery and decreased false negatives. Assaying larger plasma volumes by Mega-iSCA lowered the theoretical limit of detection for HIV-1 RNA to 0.05 copies/ mL and improved sensitivity for persistent viremia. iSCA and Mega-iSCA should be useful for measuring the impact of therapeutic interventions and in differentiating between “functional” and “sterilizing” cures of HIV-1.